In recent years, Epstein-Barr virus (EBV) lytic infection has been shown to significantly contribute to carcinogenesis. Thus, therapies aimed at targeting the EBV lytic cycle have been developed as novel strategies for treatment of EBV-associated malignancies. In this review, focusing on the viral lytic proteins, we describe recent advances regarding the involvement of the EBV lytic cycle in carcinogenesis. Moreover, we further discuss 2 distinct EBV lytic cycle-targeted therapeutic strategies against EBV-induced malignancies. One of the strategies involves inhibition of the EBV lytic cycle by natural compounds known to have anti-EBV properties; another is to intentionally induce EBV lytic replication in combination with nucleotide analogues. Recent advances in EBV lytic-based strategies are beginning to show promise in the treatment and/or prevention of EBV-related tumors.
including nasopharyngeal carcinoma (NPC), Burkitt's lymphoma (BL), Hodgkin's lymphoma, and gastric cancer. Several latent proteins, such as LMP1, LMP2A, and EBNA1, are considered to show obvious carcinogenic activities. 3 Upon reactivation induced by various stimuli, EBV undergoes 3 consecutive lytic stages, including immediate early (IE), early (E), and late (L) stages. The IE proteins, Zta and Rta, activate transcription from the promoters of lytic E genes, which trigger EBV genomic DNA replication from the lytic origin of replication, oriLyt. Then the lytic L genes that encode structural proteins are expressed, followed by viral genome packaging into infectious virion particles. In recent years, the EBV lytic cycle has been reported to contribute to carcinogenesis of several cancer types. In the present study, we highlight recent findings related to the roles of EBV lytic proteins in carcinogenesis. Furthermore, we discuss therapeutic strategies aimed at targeting the viral lytic cycle for patients with EBV-associated malignancies.
| EPSTEIN-BARR VIRUS LYTIC PROTE INS IN CARCINOGENESIS
Accumulating data suggest the contribution of the EBV lytic cycle to carcinogenesis through the induction of oncogenic cytokine secretion and genome instability. 4 During the lytic cycle, EBV expresses a series of intriguing proteins. These proteins show homology to a wide variety of cytokines and anti-apoptotic proteins. They can also enhance genomic instability or target tumor suppressors, thereby making a significant contribution to human pathology (Table 1) .
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| Zta
Zta is a transcription factor that binds to and activates the EBV lytic E gene promoters, thereby triggering EBV reactivation from latency.
Enhanced Zta expression has been shown to cause lymphomas in vivo. 13 Zta contributes to secretion of immunosuppressive cytokines, including interleukin-10 (IL-10) 14 and IL-13, 15 and also plays an important role in tumor growth through release of vascular endothelial growth factor (VEGF). 16 Beyond that, Zta reportedly inhibits tumor necrosis factor alpha (TNFa)-induced apoptosis by downregulating TNF receptor 1 (TNF-R1). 
| BHRF1
BHRF1 is an early lytic protein that shows both sequence and functional homology to the human anti-apoptotic protein Bcl-2 and inhi- mice, suggesting that it could act as a growth factor to induce tumor formation in vivo. 24 Moreover, BARF1 promotes cancer cell survival by activating the expression of the anti-apoptotic Bcl-2 protein. 25 
| BGLF4 and BGLF5
The lytic E genes, BGLF4 and BGLF5, encode a Ser/Thr kinase and an alkaline DNase, respectively. Recent studies indicate that both BGLF4 and BGLF5 induce the DNA damage signal that eventually leads to genomic instability, which consequently contributes to the carcinogenesis of human epithelial cells.
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| BALF3
BALF3 is a homologue of the enzyme, terminase, which is involved in viral DNA synthesis and packaging. 28 
| BCRF1
BCRF1 is a homologue of cellular IL-10. Recently, Han et al 29 provided evidence showing that the distribution of the vIL-10 variant types is tumor-specific and is found in lymphoma, NPC, and EBVassociated gastric carcinoma (EBVaGC), implying a pathogenic role in these diseases.
| BILF1
BILF1 is an EBV-encoded constitutively active G protein-coupled receptor (GPCR) that modulates various intracellular signaling pathways, including CRE (cAMP response element) and nuclear factor kappa B (NF-jB), through Ga i . 30 and PI3-K/Akt pathways. 7 Curcumin, the main yellow bioactive component of turmeric, suppresses BZLF1 gene transcription. 39 Resveratrol (RV) was shown to inhibit EBV lytic gene expression and production of viral particles by suppressing the activation of redoxsensitive transcription factors NF-jB and activator protein 1(AP-1). 40 At the concentrations used for inhibition of EBV reactivation, RV inhibits the proliferation of BL cells without increasing cell death. 40 The histone deacetylase (HDAC) inhibitor sulforaphane (SFN) has the potential to be consumed as a dietary compound for prevention of EBV reactivation by reducing the transcription of the BRLF1 gene. 41 
| Flavonoids
Koyama et al 42 first found a correlation between the antioxidant potential of flavonoids and inhibition of EBV lytic replication. Protoapigenone reduces the ability of Zta but not Rta to activate transcription from lytic promoters in B lymphoma cells. 43 A recent study indicated that luteolin could inhibit EBV reactivation by decreasing the promoter activities of both BZLF1 and BRLF1 genes, and thus repress NPC tumorigenesis in a mouse model. 44 F I G U R E 1 Lytic-inducing therapy for Epstein-Barr virus (EBV)-positive tumors. Upon reactivation by lytic-inducing agents, EBV enters into the lytic form of infection. During the lytic cycle, EBV expresses EBV-PK, a Ser/Thr protein kinase, which phosphorylates and thus converts the prodrug, ganciclovir (GCV), into its active, cytotoxic form in EBV-infected cells. Phosphorylated GCV ( P GCV) interferes with host DNA polymerase, leading to early termination of DNA replication and thus cell death. Phosphorylated GCV can be transferred to adjacent cells, thus inducing "bystander" killing. The intentional induction of the EBV lytic cycle can enhance GCV-induced cytotoxicity, which has been developed as a novel therapy against EBV-positive tumors
| Terpenoids
Andrographolide is extracted from Andrographis paniculata. Lin and colleagues reported that andrographolide effectively inhibited EBV lytic replication by reducing the expression of Zta and Rta in P3HR1 cells. 45 Moronic acid, found in the galls of Rhus chinensis and Brazilian propolis, suppresses the ability of Rta but not Zta to transactivate lytic early promoters. 46 
| Lignans and saponins
Lignans such as emodin 47 and saponins such as glycyrrhizic acid 48 were also reported to inhibit the expression of EBV IE proteins and EBV DNA replication.
Additionally, cordyceps has been shown to be a novel chemical suppressor of EBV lytic reactivation. 49 A recent clinical study suggests that high-dose vitamin C results in the reduction of EBV EA IgG and VCA IgM antibody levels in patients with EBV infection. 50 
| LYTIC-INDUCTION THERAPY FOR EBV-POSITIVE TUMORS
It is already well established that expression of the herpes simplex virus thymidine kinase gene allows tumor cells to be killed by ganciclovir (GCV). 51 During the lytic phase of infection, EBV expresses 2 specific kinases, thymidine kinase (TK) and protein kinase (PK). EBV-PK rather than EBV-TK phosphorylates and converts the prodrug GCV into its active, cytotoxic form in EBV-infected cells. 52 Active GCV interferes with the viral and host DNA polymerase to lead to early termination of DNA replication and cell death of tumor cells, which enables exposure of EBV to host immune surveillance. Also, phosphorylated GCV can be transferred to adjacent cells, thus inducing "bystander" killing. 53 Thus, the intentional induction of the EBV lytic cycle in EBV-positive tumor cells may be developed as a novel therapy for EBV-related tumors (Figure 1 ).
For this purpose, searching for agents that induce EBV reactivation seems imperative. Diverse small molecules have been identified as stimulators of EBV lytic replication (Table 3) . For example, TPA, sodium butyrate (SB), 54 trichostatin A (TSA), 55 and 5-aza-2 0 -deoxycytidine (5-AZA) 56 
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